Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$51.35

-0.29 (-0.56%)

, CELG

Celgene

$90.71

0.03 (0.03%)

09:07
02/20/19
02/20
09:07
02/20/19
09:07

Bristol-Myers says Celgene deal remains on track to close in Q3

Bristol-Myers Squibb Company (BMY) provided an update on its proposed acquisition of Celgene Corporation (CELG). Bristol-Myers Squibb announced that it has filed an amended registration statement on Form S-4 with the Securities and Exchange Commission in connection with Bristol-Myers Squibb's proposed acquisition of Celgene. The special meetings of stockholders of both Bristol-Myers Squibb and Celgene are currently scheduled for April 12, 2019, and the record dates for stockholders of both companies eligible to vote at the respective special meetings have been set for March 1, 2019. At the special meetings, stockholders of the respective companies will vote on proposals related to the definitive merger agreement between the two companies announced on January 3, 2019. Bristol-Myers Squibb is continuing its engagement with regulatory authorities in connection with the transaction. In order to facilitate continued dialogue with the Federal Trade Commission, Bristol-Myers Squibb determined to voluntarily withdraw and refile its premerger notification and report form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. Bristol-Myers Squibb expects to refile its premerger notification and report form under the HSR Act on February 20, 2019, which will restart the 30-day time frame for the FTC's initial review of the transaction. The transaction remains on track to close in the third quarter of 2019.

BMY

Bristol-Myers

$51.35

-0.29 (-0.56%)

CELG

Celgene

$90.71

0.03 (0.03%)

  • 20

    Feb

  • 28

    Feb

  • 18

    May

  • 20

    May

BMY Bristol-Myers
$51.35

-0.29 (-0.56%)

01/23/19
MZHO
01/23/19
NO CHANGE
Target $81
MZHO
Buy
Mizuho sees 'significant upside' in Nektar shares, reiterates $81 price target
While shares of Nektar Therapeutics (NKTR) have performed strongly year-to-date, "significant upside remains," Mizuho analyst Difei Yang tells investors in a research note. A recent Nature article on IL-2 immunotherapy and new players in the field provide support for Nektar's approach to immuno-oncology, says Yang. Further, she believes the company's collaborations with large pharma, including Bristol-Myers Squibb (BMY) and Pfizer, underscore the "strong potential" of NKTR-214. With multiple data readouts expected in 2019, Yang sees "significant value" in Nektar shares. She reiterates a Buy rating on the name with an $81 price target. The stock closed yesterday down 3% to $44.76.
01/24/19
ADAM
01/24/19
NO CHANGE
Target $161
ADAM
Buy
Bluebird Bio's bb2121 'too valuable' for Bristol-Myers to share, says Canaccord
Assuming that the Bristol-Myers (BMY) and Celgene (CELG) transaction closes, Canaccord analyst John Newman said he expects Bristol-Myers will seek 100% control of bb2121 from Bluebird Bio (BLUE), calling the treatment "too valuable" to share due to the large long-term commercial potential and Bristol's deep expertise in commercialization. Stating that Bristol-Myers could try to acquire 100% control of bb2121 from Bluebird via a buyout, U.S. royalty, or higher EU royalty, Newman added that Bristol and Celgene do not have right of first refusal if an acquirer were to tender an offer, which he calls a "favorable setup" for Bluebird shareholders. The analyst, who estimates a Bluebird buyout to obtain the other half of the company could be valued at $8.8B-$10.5B, keeps a Buy rating and $161 price target on Bluebird Bio shares.
02/01/19
JEFF
02/01/19
DOWNGRADE
Target $95
JEFF
Hold
Celgene downgraded to Hold from Buy at Jefferies
Jefferies analyst Michael Yee reiterated his view that Bristol-Myers Squibb's (BMY) acquisition of Celgene (CELG) should continue on track and will likely close, though he noted that the spread has come in and that Celgene's comments on its earnings call suggest the potential for an earlier rather than later than expected closing of the deal. Yee keeps a $95 price target on Celgene shares, but downgrade the stock to Hold from Buy given that the upside he sees from current levels is less than 15%.
02/11/19
GUGG
02/11/19
NO CHANGE
GUGG
Neutral
Patent ruling positive for Celgene and Bristol-Myers, says Guggenheim
Guggenheim analyst Seamus Fernandez said the Patent Trial and Appeal Board's decision denying Dr. Reddy's (RDY) inter partes review petition seeking to invalidate 3 Revlimid myelodysplastic syndrome patents expiring April 2023 is a positive for Celgene's (CELG) shareholders as well as for the combination with Bristol-Myers (BMY). Consistent with his below-consensus estimates for Revlimid, he continues to view a broad settlement, beginning with Dr. Reddy's, as the most likely outcome, Fernandez tells investors. He keeps a Neutral rating on Bristol-Myers shares.
CELG Celgene
$90.71

0.03 (0.03%)

01/31/19
RILY
01/31/19
UPGRADE
Target $3.25
RILY
Buy
B. Riley FBR upgrades Geron to Buy ahead of pivotal Phase III trial
B. Riley FBR analyst George Zavoico upgraded Geron (GERN) to Buy from Neutral and raised his price target for the shares to $3.25 from $1.50. The analyst believes investors should focus on the pivotal Phase III trial of imetelstat. Geron is initiating the pivotal portion of its Phase 3 trial in mid-year, which could lead to FDA approval in 2023, says Zavoico. He sees U.S. sales reaching $250M in 2024 and $750M in 2026. The drug "could meet an unmet medical need and provide a meaningful clinical benefit" for myelodysplastic syndrome patients, Zavoicotells investors in a research note. He expects both imetelstat and Celgene (CELG) and Acceleron's (XLRN) Luspatercept to be approved for MDS and be "widely used in treating mostly different subgroups." Shares of Geron are up 11%, or 11c, to $1.14 in premarket trading.
01/31/19
PIPR
01/31/19
NO CHANGE
PIPR
Celgene reports 'solid' Q4, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond maintained a Neutral rating and $85 price target on Celgene shares after the company reported "solid" Q4 results, with all major brands -- Revlimid, Pomalyst, Abraxane and Otezla -- performing better than consensus, and timelines for ozanimod, liso-cel, and bb2121 still looking to be on track. Celgene also reiterated its FY19 guidance, which the analyst noted was generally in-line with the firm's estimates.

TODAY'S FREE FLY STORIES

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

19:35
09/22/19
09/22
19:35
09/22/19
19:35
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

DB

Deutsche Bank

$7.99

-0.08 (-0.99%)

BNPQY

BNP Paribas

$0.00

(0.00%)

JNJ

Johnson & Johnson

$131.73

1.75 (1.35%)

TEVA

Teva

$7.44

-0.08 (-1.06%)

ENDP

Endo

$3.48

0.115 (3.42%)

MNK

Mallinckrodt

$2.46

0.01 (0.41%)

ABT

Abbott

$83.56

0.35 (0.42%)

AMRX

Amneal Pharmaceuticals

$3.34

0.21 (6.71%)

MYL

Mylan

$21.01

0.03 (0.14%)

MCK

McKesson

$146.83

1.06 (0.73%)

CAH

Cardinal Health

$47.89

-0.14 (-0.29%)

ABC

AmerisourceBergen

$85.13

0.475 (0.56%)

WAB

Wabtec

$74.01

0.26 (0.35%)

CVS

CVS Health

$64.28

0.65 (1.02%)

REAL

RealReal

$17.00

0.21 (1.25%)

CMG

Chipotle

$835.17

3.67 (0.44%)

MCD

McDonald's

$209.44

-1.12 (-0.53%)

YUM

Yum! Brands

$112.31

-1.83 (-1.60%)

WEN

Wendy's

$20.77

0.22 (1.07%)

QSR

Restaurant Brands

$72.64

-1.24 (-1.68%)

CMCSA

Comcast

$46.36

-0.32 (-0.69%)

CMCSK

Comcast

$0.00

(0.00%)

DAL

Delta Air Lines

$58.63

-0.05 (-0.09%)

FANG

Diamondback Energy

$96.90

-0.45 (-0.46%)

EHC

Encompass Health

$64.41

-0.01 (-0.02%)

FB

Facebook

$189.88

-0.27 (-0.14%)

MSFT

Microsoft

$139.34

-1.74 (-1.23%)

PG

Procter & Gamble

$122.22

0.37 (0.30%)

KO

Coca-Cola

$53.90

-0.62 (-1.14%)

PEP

PepsiCo

$134.49

-0.98 (-0.72%)

CL

Colgate-Palmolive

$70.97

0.01 (0.01%)

KMB

Kimberly-Clark

$135.13

0.9 (0.67%)

K

Kellogg

$63.79

0.07 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 23

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 01

    Oct

  • 02

    Oct

  • 02

    Oct

  • 02

    Oct

  • 03

    Oct

  • 08

    Oct

  • 10

    Oct

  • 15

    Oct

  • 16

    Oct

  • 18

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 01

    Nov

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

BGNE

BeiGene

$135.62

2.61 (1.96%)

19:34
09/22/19
09/22
19:34
09/22/19
19:34
Hot Stocks
BeiGene announces results on Tislelizumab from ongoing clinical trials »

BeiGene announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 15

    Oct

  • 27

    Feb

CE

Celanese

$122.73

-1.06 (-0.86%)

19:24
09/22/19
09/22
19:24
09/22/19
19:24
Hot Stocks
Celanese experiences emergency incident at Clear Lake facility »

Celanese experienced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$379.33

-5.28 (-1.37%)

19:21
09/22/19
09/22
19:21
09/22/19
19:21
Periodicals
Indonesia to fault 737 Max design, oversight lapses in Lion Air crash, WSJ says »

Indonesian investigators…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

AA

Alcoa

$21.70

-0.26 (-1.18%)

19:15
09/22/19
09/22
19:15
09/22/19
19:15
Downgrade
Alcoa rating change  »

Alcoa downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

CMC

Commercial Metals

$17.94

-0.42 (-2.29%)

, SCHN

Schnitzer Steel

$23.55

-0.27 (-1.13%)

19:15
09/22/19
09/22
19:15
09/22/19
19:15
Downgrade
Alcoa downgraded to Neutral from Buy at Goldman Sachs »

Goldman Sachs analyst…

CMC

Commercial Metals

$17.94

-0.42 (-2.29%)

SCHN

Schnitzer Steel

$23.55

-0.27 (-1.13%)

AA

Alcoa

$21.70

-0.26 (-1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

CMC

Commercial Metals

$17.94

-0.42 (-2.29%)

19:08
09/22/19
09/22
19:08
09/22/19
19:08
Downgrade
Commercial Metals rating change  »

Commercial Metals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHN

Schnitzer Steel

$23.55

-0.27 (-1.13%)

19:06
09/22/19
09/22
19:06
09/22/19
19:06
Downgrade
Schnitzer Steel rating change  »

Schnitzer Steel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNSR

Finisar

$24.31

1.25 (5.42%)

18:15
09/22/19
09/22
18:15
09/22/19
18:15
Hot Stocks
Finisar presents new products, technologies at ECOC 2019 »

Finisar introduced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BNPQY

BNP Paribas

$0.00

(0.00%)

, DB

Deutsche Bank

$7.99

-0.08 (-0.99%)

18:04
09/22/19
09/22
18:04
09/22/19
18:04
Periodicals
Deutsche Bank nearing deal to transfer prime assets to BNP, Reuters says »

Deutsche Bank (DB) is…

BNPQY

BNP Paribas

$0.00

(0.00%)

DB

Deutsche Bank

$7.99

-0.08 (-0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRSK

Verisk Analytics

$158.47

-0.21 (-0.13%)

18:00
09/22/19
09/22
18:00
09/22/19
18:00
Initiation
Verisk Analytics initiated at Keefe Bruyette »

Verisk Analytics assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.92

0.78 (2.10%)

, CMCSA

Comcast

$46.36

-0.32 (-0.69%)

16:58
09/22/19
09/22
16:58
09/22/19
16:58
On The Fly
Box Office Battle: 'Downton Abbey' wins weekend with $31M »

"Box Office Battle" is…

T

AT&T

$37.92

0.78 (2.10%)

CMCSA

Comcast

$46.36

-0.32 (-0.69%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$59.19

-0.19 (-0.32%)

LGF.A

Lionsgate

$9.49

-0.47 (-4.72%)

LGF.B

Lionsgate

$8.88

-0.435 (-4.67%)

DIS

Disney

$132.18

-1.14 (-0.86%)

VIAB

Viacom

$24.92

-0.28 (-1.11%)

VIA

Viacom

$26.67

-0.85 (-3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Sep

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

VIVHY

Vivendi

$0.00

(0.00%)

, MDSO

Medidata

$91.77

-0.04 (-0.04%)

16:01
09/22/19
09/22
16:01
09/22/19
16:01
Periodicals
Vivendi to widen legal battle against Mediaset beyond Italy, Reuters says »

Vivendi (VIVHY) is taking…

VIVHY

Vivendi

$0.00

(0.00%)

MDSO

Medidata

$91.77

-0.04 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

15:57
09/22/19
09/22
15:57
09/22/19
15:57
Periodicals
Some WeWork board members seeing to remove Neumann as CEO, WSJ says »

A bloc of WeWork…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

15:54
09/22/19
09/22
15:54
09/22/19
15:54
Periodicals
SoftBank turns against WeWork's parent CEO, Reuters reports »

SoftBank (SFTBY), the…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIAB

Viacom

$24.92

-0.28 (-1.11%)

, VIA

Viacom

$26.67

-0.85 (-3.09%)

15:48
09/22/19
09/22
15:48
09/22/19
15:48
Hot Stocks
Viacom acquires exclusive cable rights to Seinfeld from Sony Pictures Television »

Viacom (VIAB, VIA)…

VIAB

Viacom

$24.92

-0.28 (-1.11%)

VIA

Viacom

$26.67

-0.85 (-3.09%)

SNE

Sony

$59.19

-0.19 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Sep

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

PWR

Quanta Services

$37.61

-0.28 (-0.74%)

12:22
09/22/19
09/22
12:22
09/22/19
12:22
Conference/Events
Quanta Services management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 13

    Nov

PTEN

Patterson-UTI

$9.66

0.01 (0.10%)

12:21
09/22/19
09/22
12:21
09/22/19
12:21
Conference/Events
Patterson-UTI management to meet with Stephens »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

ESE

Esco Technologies

$78.44

-1.54 (-1.93%)

12:19
09/22/19
09/22
12:19
09/22/19
12:19
Conference/Events
Esco Technologies management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

CSGP

CoStar Group

$595.10

-3.87 (-0.65%)

12:16
09/22/19
09/22
12:16
09/22/19
12:16
Conference/Events
CoStar Group participates in a conference call with Stephens »

Conference call with CFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

  • 13

    Nov

CNNE

Cannae Holdings

$28.05

0.875 (3.22%)

12:02
09/22/19
09/22
12:02
09/22/19
12:02
Conference/Events
Cannae Holdings management to meet with Stephens »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 13

    Nov

ANDE

Andersons

$26.28

-0.56 (-2.09%)

12:01
09/22/19
09/22
12:01
09/22/19
12:01
Conference/Events
Andersons management to meet with Stephens »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 13

    Nov

XGN

Exagen

$18.16

-0.425 (-2.29%)

, DDOG

Datadog

$36.20

-1.26 (-3.36%)

08:40
09/22/19
09/22
08:40
09/22/19
08:40
On The Fly
Opening Day: Datadog rises over 50% in market debut »

Shares of Datadog surged…

XGN

Exagen

$18.16

-0.425 (-2.29%)

DDOG

Datadog

$36.20

-1.26 (-3.36%)

PING

Ping Identity

$19.25

-0.8 (-3.99%)

IGMS

IGM Biosciences

$21.00

-0.7 (-3.23%)

NVST

Envista

$28.80

0.75 (2.67%)

PTON

Peloton

$0.00

(0.00%)

EDR

Endeavor

$0.00

(0.00%)

OPRT

Oportun Financial

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

CSCO

Cisco

$49.59

0.38 (0.77%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Oct

  • 13

    Nov

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

PG

Procter & Gamble

$122.22

0.37 (0.30%)

, KO

Coca-Cola

$53.90

-0.62 (-1.14%)

08:17
09/21/19
09/21
08:17
09/21/19
08:17
Periodicals
Kellogg, Coca-Cola among staples stocks for dividends, Barron's says »

Consumer-staples stocks…

PG

Procter & Gamble

$122.22

0.37 (0.30%)

KO

Coca-Cola

$53.90

-0.62 (-1.14%)

PEP

PepsiCo

$134.49

-0.98 (-0.72%)

CL

Colgate-Palmolive

$70.97

0.01 (0.01%)

KMB

Kimberly-Clark

$135.13

0.9 (0.67%)

K

Kellogg

$63.79

0.07 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 01

    Oct

  • 03

    Oct

  • 08

    Oct

  • 18

    Oct

  • 22

    Oct

  • 29

    Oct

  • 01

    Nov

CMCSA

Comcast

$46.36

-0.32 (-0.69%)

, CMCSK

Comcast

$0.00

(0.00%)

08:09
09/21/19
09/21
08:09
09/21/19
08:09
Periodicals
Facebook, Microsoft among growth stocks for risky times, Barron's says »

Comcast (CMCSA), Delta…

CMCSA

Comcast

$46.36

-0.32 (-0.69%)

CMCSK

Comcast

$0.00

(0.00%)

DAL

Delta Air Lines

$58.63

-0.05 (-0.09%)

FANG

Diamondback Energy

$96.90

-0.45 (-0.46%)

EHC

Encompass Health

$64.41

-0.01 (-0.02%)

FB

Facebook

$189.88

-0.27 (-0.14%)

JNJ

Johnson & Johnson

$131.73

1.75 (1.35%)

MSFT

Microsoft

$139.34

-1.74 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 01

    Oct

  • 02

    Oct

  • 15

    Oct

  • 24

    Oct

  • 27

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.